%0 Journal Article
%T Identifying SCS Trial Responders Immediately After Postoperative Programming with ECAP Dose-Controlled Closed-Loop Therapy.
%A Pope JE
%A Antony A
%A Petersen EA
%A Rosen SM
%A Sayed D
%A Hunter CW
%A Goree JH
%A Vu CM
%A Bhandal HS
%A Shumsky PM
%A Bromberg TA
%A Smith GL
%A Lam CM
%A Kalia H
%A Lee JM
%A Khurram A
%A Gould I
%A Karantonis DM
%A Deer TR
%J Pain Ther
%V 0
%N 0
%D 2024 Jul 9
%M 38977651
暂无%R 10.1007/s40122-024-00631-4
%X <B>BACKGROUND: </B>Drawbacks of fixed-output spinal cord stimulation (SCS) screening trials may lead to compromised trial outcomes and poor predictability of long-term success. Evoked compound action potential (ECAP) dose-controlled closed-loop (CL) SCS allows objective confirmation of therapeutic neural activation and pulse-to-pulse stimulation adjustment. We report on the immediate patient-reported and neurophysiologic treatment response post-physiologic CL-SCS and feasibility of early SCS trial responder prediction.<BR><B>METHODS: </B>Patient-reported pain relief, functional improvement, and willingness to proceed to permanent implant were compared between the day of the trial procedure (Day 0) and end of trial (EOT) for 132 participants in the ECAP Study undergoing a trial stimulation period. ECAP-based neurophysiologic measurements from Day 0 and EOT were compared between responder groups.<BR><B>RESULTS: </B>A high positive predictive value (PPV) was achieved with 98.4% (60/61) of patients successful on the Day 0 evaluation also responding at EOT. The false-positive rate (FPR) was 5.6% (1/18). ECAP-based neurophysiologic measures were not different between patients who passed all Day 0 success criteria ("Day 0 successes") and those who did not ("needed longer to evaluate the therapy"). However, at EOT, responders had higher therapeutic usage and dose levels compared to non-responders.<BR><B>CONCLUSIONS: </B>The high PPV and low FPR of the Day 0 evaluation provide confidence in predicting trial outcomes as early as the day of the procedure. Day 0 trials may be beneficial for reducing patient burden and complication rates associated with extended trials. ECAP dose-controlled CL-SCS therapy may provide objective data and rapid-onset pain relief to improve prognostic ability of SCS trials in predicting outcomes.<BR><B>BACKGROUND: </B>The ECAP Study is registered with ClinicalTrials.gov (NCT04319887).